Stromal cells play crucial roles in tumor development and are increasingly attractive targets for therapy. There are considerable racial disparities in the incidence and progression of many tumors, reflecting both environmental exposure and genetic differences existing between races. Tumorigenesis and tumor progression are linked to both the propensity to suffer an initiating event and the host response to such an event once it occurs, contributing to incidence and outcomes. In this review, we focused on racial disparities in the tumor microenvironment (TME) of different cancers as potential modulators of growth, metastasis, and response to treatment. Several studies suggest that the TME in AA has a distinct tumor biology and may facilitate both early onset and aggressive tumor growth while inhibiting anti-tumorigenic properties. The TME of AA patients often exhibits an immunosuppressive microenvironment with a substantial enrichment of immune inflammatory pathways and genes. As a result, AA patients can potentially benefit more from treatment strategies that modulate the immune system. Focusing on TME components for diagnostic and therapeutic purposes to address racial disparities is a promising area of investigation. Future basic and clinical research studies on personalized cancer diagnosis and treatment should acknowledge the significance of TME in racial disparities.
Through stromal-epithelial interactions, carcinoma associated fibroblasts (CAF) play a critical role in tumor growth and progression. Activation of erythrophoyetin-producing human hepatocellular (Eph) receptors has been implicated in cancer. Eph receptor interactions with Ephrin ligands lead to bidirectional signals in the recipient and effector cells. The consequences of continuous reverse Ephrin signaling activation in fibroblasts on prostate cancer (PCa) is unknown. When compared to benign prostate fibroblast, CAF displayed higher expression of Ephrin B1, B2, and B3 ligands (EFNB1, EFNB2, and EFNB3). In this study, we found that continuous activation of EFNB1 and EFNB3 in a benign human prostate stromal cell line (BHPrS1) increased the expression of CAF markers and induced a CAF phenotype. BHPrS1EFNB1 and BHPrS1EFNB3 displayed a pro-tumorigenic secretome with multiple effects on neovascularization, collagen deposition, and cancer cell proliferation, overall increasing tumorigenicity of a premalignant prostate epithelial cell line BPH1 and PCa cell line LNCaP, both in vitro and in vivo. Inhibition of Src family kinases (SFK) in BHPrS1EFNB1 and BHPrS1EFNB3 suppressed EFNB-induced ɑ-SMA (Alpha-smooth muscle actin) and TN-C (Tenascin-C) in vitro. Our study suggests that acquisition of CAF characteristics via SFK activation in response to increased EFNB ligands could promote carcinogenesis via modulation of TME in PCa.
DGAT1 regulates BDNF in human prostate fibroblasts. A, Cytokine array of conditioned serum from BHPrS1DGAT1 and BHPrS1EV ± U0126, technical replicates = 2, P < 0.05 (top). Quantification of cytokine array is shown as fold change over no U0126 treatment (bottom). B, Western blot (top) of pERK1/2 in high-DGAT1 expressing EACAF and AACAF cultured ± DGAT1i, n = 3. Changes in ERK activation was quantified and normalized to total ERK content (bottom), P < 0.05. C, Conditioned serum collected from high-DGAT1 expressing CAFs from AA and EA treated with ± DGAT1i for 72 hours was used for cytokine array. Densitometry values were normalized to background. Fold changes after DGAT1i exposure were calculated. Bars show selected secreted factors with significant differential racial response upon DGAT1 inhibition. Technical replicates = 2, P < 0.05. D, LNCaP and PC-3 cells were grown in the presence of two different AACAF CM treated with or without DGAT1i and compared with control cells cultured under basal conditions (see “Materials and Methods”). Cell confluency (each data point) was evaluated using Incucyte live-cell imaging over 5 days. E, Schematic illustration of CAF showing DGAT1 promotion of LD accumulation and regulation of secreted factors such as BDNF, VEGF, and TSP1 with potential roles in tumor growth, invasion, and angiogenesis. Multiple-group comparisons were analyzed by one-way ANOVA with Tukey post hoc test. *, P < 0.05. [E, Created in BioRender. Franco, O. (2026) https://BioRender.com/4jno6ge.]
DGAT1 increases LD density in BHPrS1 cells. A, BHPrS1DGAT1 and BHPrS1EV cells were exposed to OA and/or DGAT1 inhibitor (DGAT1i) n = 3 and harvested for flow cytometry. A dot plot of SSC (y-axis) vs. forward scatter (FSC; x-axis) of BHPrS1 cells shows the granularity distribution divided into two gates that included the LDD-low region, representing many cells under basal conditions (blue edges of the contour plot), and LDD-high regions. Analysis of LD density based on the percentage of cells in the LDD-high gate (right). Note: OA(−) plots are the same as those displayed in Fig. 2B for cell counts. B, Nile Red (red) staining to visualize LD content was performed in BHPrS1DGAT1 and BHPrS1EV cells (n = 3) exposed to OA and/or DGAT1i and imaged by confocal microscopy (left). Scatter dot plot (right) of LD size and count distribution obtained from ALDQ analyzed images BHPrS1DGAT1 (green: −OA, blue: +OA) and BHPrS1EV (orange: −OA, red: +OA). C, Dot plot of LD size from BHPrS1DGAT1 and BHPrS1EV exposed to a combination of OA and DGAT1i. D, Scatter dot plot of nLD size and count distribution from BHPrS1DGAT1 and BHPrS1EV cells exposed to OA. Two-group comparisons were analyzed by two-tailed, unpaired Student t test; multiple-group comparisons were analyzed by one-way ANOVA with Tukey post hoc test. *, P < 0.05.
Molecular differences of engineered cell lines. A, Volcano plot of RNA-seq data from BHPrS1DGAT1 cells compared with BHPrS1EV control cells. Fold change (Log2 = >1) calculated comparing BHPrS1DGAT1 to BHPrS1EV. (red = upregulation, green = downregulation, blue = no change) DESeq2 R package (1.42.0; RRID: SCR_000154), P < 0.05 adjusted with the Benjamini and Hochberg method. B, Pathway analysis heatmap showing significant gene alterations (red = upregulation, green = downregulation) in BHPrS1DGAT1 cells compared with BHPrS1EV control cells. clusterProfiler R package, P < 0.05. C, Top, qRT-PCR BDNF expression in BHPrS1DGAT1 vs. BHPrS1EV. Bottom, primary benign prostate fibroblasts isolated from prostate tissues were transiently transfected with the DGAT1 or empty vector (EV) plasmids. Expression of BDNF was assessed by qRT-PCR and compared between groups *, t test, P < 0.05. D, Conditioned media were collected from BHPrS1DGAT1 and BHPrS1EV cells for the assessment of secreted factors using a cytokine array. After normalization and background subtraction, data are presented as log2 fold change over BHPrS1EV. Blot of selected secreted factors (duplicates) with evident changes between BHPrS1DGAT1 and BHPrS1EV groups are shown (left). Analysis of cytokines with significant changes (t test, P < 0.05) shows upregulated (red bars) and downregulated (blue bars) targets (right). E, Western blot analysis of downstream target pathways regulated in BHPrS1DGAT1 and compared with BHPrS1EV cells. Densitometric analysis of Western blot images. N = 3, *, Two-group comparisons were analyzed by two-tailed, unpaired Student t test. *, P < 0.05.